C OSBORNE to Clinical Trials as Topic
This is a "connection" page, showing publications C OSBORNE has written about Clinical Trials as Topic.
Connection Strength
0.367
-
Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233-47.
Score: 0.061
-
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 2):1049s-1055s.
Score: 0.043
-
Consensus statement: Expedition Inspiration 2004 Breast Cancer Symposium 'Breast Cancer--The Development and Validation of New Therapeutics'. Breast Cancer Res Treat. 2005 Mar; 90(1):1-3.
Score: 0.041
-
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004 Mar; 90 Suppl 1:S2-6.
Score: 0.038
-
Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000 Sep; 18(17):3172-86.
Score: 0.030
-
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896. Ann N Y Acad Sci. 1996 Apr 30; 784:325-35.
Score: 0.022
-
Current trials and future directions of the Southwest Oncology Group Breast Cancer Committee. Cancer. 1994 Aug 01; 74(3 Suppl):1135-8.
Score: 0.020
-
Mechanisms of tamoxifen resistance. Breast Cancer Res Treat. 1994; 32(1):49-55.
Score: 0.019
-
Targeting the EGF receptor in breast cancer treatment. Breast Cancer Res Treat. 1994; 32(1):97-103.
Score: 0.019
-
Dose intensity as a therapeutic strategy in breast cancer. Breast Cancer Res Treat. 1991 Dec; 20 Suppl:S11-4.
Score: 0.016
-
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient. Clin Cancer Res. 2011 Sep 01; 17(17):5559-61.
Score: 0.016
-
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res. 2009 Aug 15; 15(16):5258-66.
Score: 0.014
-
Adjuvant therapy in node-negative breast cancer. A panel discussion. Breast Cancer Res Treat. 1989 Mar; 13(2):97-115.
Score: 0.013
-
Adjuvant therapy of breast cancer: Southwest Oncology Group studies. NCI Monogr. 1986; (1):71-4.
Score: 0.011
-
Adjuvant therapy for breast cancer with positive axillary nodes designed according to estrogen receptor status. J Steroid Biochem. 1985 Dec; 23(6B):1151-4.
Score: 0.003
-
A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study). Invest New Drugs. 1985; 3(2):149-52.
Score: 0.003